Dbv Technologies ROCE 2024

Dbv Technologies Aktienanalyse

What does Dbv Technologies do?

DBV Technologies SA (DBV) is a biopharmaceutical company specializing in the development of therapies for allergic diseases. The company was founded in 2002 by Pierre-Henri Benhamou in France. Its objective is to set new standards in the treatment of allergies through innovative approaches. DBV's business model is based on the research and development of products based on epicutaneous tests (application of allergens on the skin). This alternative method to the common oral immunotherapy (OIT) treats allergic reactions using special patch products. These patches contain the allergens that trigger an allergic reaction in the patient. Through continuous contact with the allergens, the body's defense mechanisms learn that there is no threat and suppress the allergic reaction. DBV offers two products based on epicutaneous tests: Viaskin Peanut and Viaskin Milk. Viaskin Peanut is DBV's first product for the treatment of peanut allergies, while Viaskin Milk is the next product in the pipeline. Viaskin Peanut is a patch that contains a microdose of peanut protein. It is applied to the patient's skin, gradually familiarizing the immune system with the allergen and reducing allergic reactions. The patch can also be used in children, making it an important innovation in the treatment of peanut allergies. Viaskin Milk is also a patch that contains specific proteins found in milk. This patch aims to revolutionize the treatment of milk intolerances, as there are currently no specific therapies for this type of allergy. Again, this is an epicutaneous test. DBV has previously entered into several partnerships with other companies. This includes a collaboration with Nestle to further expand the potential of epicutaneous test products. Networking with insurers and health insurance companies is also an important strategic step in establishing the use of epicutaneous test products in practice. The company is particularly active in Europe and the USA. Its IPO took place in 2012. In 2017, DBV became the first French drug manufacturer to receive approval from the European Medicines Agency (EMA) for Viaskin Peanut. DBV Technologies SA has great potential in the development of epicutaneous products for long-term treatment of allergies. The company has achieved promising results in a short period of time and has established itself as an innovative player in the field of allergology. Dbv Technologies ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROCE Details

Unraveling Dbv Technologies's Return on Capital Employed (ROCE)

Dbv Technologies's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing Dbv Technologies's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

Dbv Technologies's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in Dbv Technologies’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about Dbv Technologies stock

What is the ROCE (Return on Capital Employed) of Dbv Technologies this year?

The ROCE of Dbv Technologies is -0.54 undefined this year.

How has the ROCE (Return on Capital Employed) of Dbv Technologies developed compared to the previous year?

The ROCE of Dbv Technologies has increased by 9.93% increased compared to the previous year.

What does a high ROCE (Return on Capital Employed) mean for investors of Dbv Technologies?

A high Return on Capital Employed (ROCE) indicates that Dbv Technologies has efficient capital utilization and is able to achieve a higher return on its invested capital. This can be appealing to investors.

What does a low ROCE (Return on Capital Employed) mean for investors of Dbv Technologies?

A low ROCE (Return on Capital Employed) can indicate that Dbv Technologies has an inefficient utilization of its capital and may have difficulty in achieving a satisfactory return on its invested capital. This can be uncertain or unattractive for investors.

How does an increase in ROCE from Dbv Technologies impact the company?

An increase in the ROCE of Dbv Technologies can be an indicator of improved company efficiency and show that it is achieving higher profits in relation to its investments.

How does a reduction in the ROCE of Dbv Technologies affect the company?

A decrease in ROCE of Dbv Technologies can be an indicator of deteriorated efficiency of the company, indicating that it is generating lower profits in relation to its investments.

What are some factors that can influence the ROCE of Dbv Technologies?

Some factors that can affect Dbv Technologies's ROCE include efficiency in managing assets, profitability of investments, cost efficiency, and market conditions.

Why is the ROCE of Dbv Technologies so important for investors?

The ROCE of Dbv Technologies is important for investors as it is an indicator of the company's efficiency and shows how successful the company is in relation to its investments. A high ROCE can indicate strong financial performance of the company.

What strategic measures can Dbv Technologies take to improve the ROCE?

To improve the ROCE, Dbv Technologies can take measures such as increasing efficiency in asset management, optimizing investments, cost savings, and exploring new revenue sources. It is important for the company to conduct a thorough review of its operations to determine the best strategic actions to improve the ROCE.

How much dividend does Dbv Technologies pay?

Over the past 12 months, Dbv Technologies paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Dbv Technologies is expected to pay a dividend of 0 USD.

What is the dividend yield of Dbv Technologies?

The current dividend yield of Dbv Technologies is .

When does Dbv Technologies pay dividends?

Dbv Technologies pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Dbv Technologies?

Dbv Technologies paid dividends every year for the past 0 years.

What is the dividend of Dbv Technologies?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Dbv Technologies located?

Dbv Technologies is assigned to the 'Health' sector.

Wann musste ich die Aktien von Dbv Technologies kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Dbv Technologies from 9/21/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/21/2024.

When did Dbv Technologies pay the last dividend?

The last dividend was paid out on 9/21/2024.

What was the dividend of Dbv Technologies in the year 2023?

In the year 2023, Dbv Technologies distributed 0 USD as dividends.

In which currency does Dbv Technologies pay out the dividend?

The dividends of Dbv Technologies are distributed in USD.